DK2365332T3 - HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser - Google Patents

HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser

Info

Publication number
DK2365332T3
DK2365332T3 DK10290124.6T DK10290124T DK2365332T3 DK 2365332 T3 DK2365332 T3 DK 2365332T3 DK 10290124 T DK10290124 T DK 10290124T DK 2365332 T3 DK2365332 T3 DK 2365332T3
Authority
DK
Denmark
Prior art keywords
hmgb1
hiv
neurological disorders
infected patients
antibodies
Prior art date
Application number
DK10290124.6T
Other languages
English (en)
Inventor
Marie-Lise Gougeon
Beatrice Poirier-Beaudoin
Valerie Seffer
Hela Saidi
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK2365332T3 publication Critical patent/DK2365332T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4029—Detecting, measuring or recording for evaluating the nervous system for evaluating the peripheral nervous systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/407—Evaluating the spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B2010/0077—Cerebrospinal fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Developmental Disabilities (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK10290124.6T 2010-03-10 2010-03-10 HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser DK2365332T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10290124.6A EP2365332B1 (en) 2010-03-10 2010-03-10 HMGB1 and anti-HMGB1 antibodies in HIV infected patients especially with neurological disorders

Publications (1)

Publication Number Publication Date
DK2365332T3 true DK2365332T3 (da) 2013-08-26

Family

ID=42289547

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10290124.6T DK2365332T3 (da) 2010-03-10 2010-03-10 HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser
DK11710151.9T DK2545380T3 (da) 2010-03-10 2011-03-10 HMGB1- og anti-HMGB1-antistoffer til prognose af neurologiske lidelser
DK14150638.6T DK2720043T3 (da) 2010-03-10 2011-03-10 HMGB1 og anti-HMGB1-antistoffer til prognose af neurologiske lidelser

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK11710151.9T DK2545380T3 (da) 2010-03-10 2011-03-10 HMGB1- og anti-HMGB1-antistoffer til prognose af neurologiske lidelser
DK14150638.6T DK2720043T3 (da) 2010-03-10 2011-03-10 HMGB1 og anti-HMGB1-antistoffer til prognose af neurologiske lidelser

Country Status (11)

Country Link
US (3) US8728748B2 (da)
EP (3) EP2365332B1 (da)
JP (3) JP5703314B2 (da)
KR (1) KR101972602B1 (da)
CN (1) CN102884432B (da)
CA (2) CA2792506C (da)
DK (3) DK2365332T3 (da)
ES (3) ES2413437T3 (da)
PL (3) PL2365332T3 (da)
PT (2) PT2365332E (da)
WO (1) WO2011110650A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0916349A2 (pt) 2008-09-11 2019-09-24 Pasteur Institut monitoramento e inibição da infecção pelo vírus da imunodeficiência humana através da modulação do desencadeamento dependete de hmgb1 da replicação e persistência do hiv-1
DK2365332T3 (da) 2010-03-10 2013-08-26 Pasteur Institut HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser
JP6249712B2 (ja) * 2013-10-09 2017-12-20 公益財団法人ヒューマンサイエンス振興財団 非傍腫瘍性急性脳炎患者の予後診断装置の作動方法
EP3067699A1 (en) * 2015-03-11 2016-09-14 Neuron Bio, S.A. Method for diagnosing alzheimer's disease
KR101734529B1 (ko) 2015-05-08 2017-05-11 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
EP3165927A1 (en) 2015-11-03 2017-05-10 Institut Pasteur An assay to detect and quantitate specific antibodies for various redox forms of hmgb1
EP3386529A2 (en) 2015-12-11 2018-10-17 Ruprecht-Karls-Universität Heidelberg Combined preparations of pkm2 modulators and hmgb1
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
JP2019152666A (ja) * 2018-03-02 2019-09-12 富士レビオ株式会社 ジカウイルスを検出する方法及びキット
CN111671895B (zh) * 2020-06-02 2022-03-08 江汉大学 抗PfHMGB1抗体在抗藻毒素试剂中的应用及抗藻毒素试剂
JP2024064487A (ja) * 2022-10-28 2024-05-14 国立大学法人 東京医科歯科大学 認知症の診断マーカー
CN119775408B (zh) * 2025-03-12 2025-05-30 武汉伊莱瑞特生物科技股份有限公司 抗猴高迁移率族蛋白b1单克隆抗体、酶联免疫检测试剂盒及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384240A (en) * 1992-11-25 1995-01-24 Akzo Nobel, N.V. Base dissociation assay
JP3472048B2 (ja) * 1995-10-09 2003-12-02 鐘淵化学工業株式会社 自己免疫疾患の診断薬
US6822078B2 (en) * 1996-07-17 2004-11-23 Kaneka Corp. Diagnostic drugs for autoimmune diseases
US6541208B1 (en) * 1998-03-17 2003-04-01 University Of Maryland Biotechnology Institute Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
US6541203B2 (en) * 1998-11-23 2003-04-01 President And Fellows Of Harvard College Detecting structural or synthetic information about chemical compounds
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
AU2005218391B2 (en) * 2004-03-05 2008-11-20 Prima Meat Packers, Ltd. Method of detecting allergen
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
JP2008520552A (ja) * 2004-10-22 2008-06-19 メディミューン，インコーポレーテッド Ｈｍｇｂ１に対する高親和性の抗体およびその使用法
JP4682307B2 (ja) * 2005-11-17 2011-05-11 財団法人ヒューマンサイエンス振興財団 Ｈｉｖウイルス生産量測定マーカー及びその利用方法
US20070154955A1 (en) * 2005-12-30 2007-07-05 Industrial Technology Research Institute Method of diagnosing autoimmune polyglandular syndrome and kits thereof
EP1981489B1 (en) * 2006-01-13 2013-05-01 The Feinstein Institute for Medical Research Inhibition of inflammatory cytokine production with tanshinones
US8026076B2 (en) * 2006-09-05 2011-09-27 Hvidovre Hospital IP-10 based immunological monitoring
US20100221700A1 (en) * 2007-01-11 2010-09-02 Haynes Barton F Method of monitoring hiv infection
BRPI0916349A2 (pt) * 2008-09-11 2019-09-24 Pasteur Institut monitoramento e inibição da infecção pelo vírus da imunodeficiência humana através da modulação do desencadeamento dependete de hmgb1 da replicação e persistência do hiv-1
DK2365332T3 (da) 2010-03-10 2013-08-26 Pasteur Institut HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser

Also Published As

Publication number Publication date
US9766254B2 (en) 2017-09-19
DK2545380T3 (da) 2015-03-09
US9164107B2 (en) 2015-10-20
CA2944657C (en) 2018-10-02
CN102884432B (zh) 2016-01-13
PT2365332E (pt) 2013-08-02
ES2413437T3 (es) 2013-07-16
US8728748B2 (en) 2014-05-20
WO2011110650A2 (en) 2011-09-15
EP2365332A1 (en) 2011-09-14
EP2545380A2 (en) 2013-01-16
PT2545380E (pt) 2015-03-16
JP6196278B2 (ja) 2017-09-13
JP5851565B2 (ja) 2016-02-03
EP2365332B1 (en) 2013-05-29
US20140308755A1 (en) 2014-10-16
EP2720043B1 (en) 2016-01-20
ES2561610T3 (es) 2016-02-29
PL2365332T3 (pl) 2013-10-31
US20130065221A1 (en) 2013-03-14
US20160018418A1 (en) 2016-01-21
EP2720043A3 (en) 2014-08-20
JP2016029397A (ja) 2016-03-03
DK2720043T3 (da) 2016-03-29
PL2545380T3 (pl) 2015-06-30
JP2014224829A (ja) 2014-12-04
KR20130038832A (ko) 2013-04-18
KR101972602B1 (ko) 2019-04-25
CA2792506A1 (en) 2011-09-15
CA2792506C (en) 2016-11-22
PL2720043T3 (pl) 2016-09-30
CN102884432A (zh) 2013-01-16
ES2532101T3 (es) 2015-03-24
CA2944657A1 (en) 2011-09-15
JP5703314B2 (ja) 2015-04-15
EP2545380B1 (en) 2014-12-10
EP2720043A2 (en) 2014-04-16
JP2013521511A (ja) 2013-06-10
WO2011110650A3 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
IL273607A (en) Humanized antibodies against liv-1, preparations containing them and their uses
PL2365332T3 (pl) HMGB1 i przeciwciała anty-HMGB1 u pacjentów zakażonych HIV, zwłaszcza z zaburzeniami neurologicznymi
IL245556B (en) A conjugate containing oxyntomodulin and a fragment of immunoglobulin, and its use
IL244197A0 (en) Antibodies against cd100 and methods of using them
IL227477B (en) Human antibodies and antibody-drug conjugates against 74cd
IL235261B (en) Antibodies against claudin 18.2 useful in cancer diagnosis
IL224441B (en) Antibodies with modified isoelectric points
IL216835A0 (en) Anti-vegf antibodies and their uses
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
IL233050A0 (en) New drug-antibody conjugates and their use
HUE058226T2 (hu) NGF elleni antitestek és alkalmazásuk
PT3043182T (pt) Anticorpos monoclonais para variantes de hemoglobina c, s, e e d
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
HRP20181811T1 (hr) Zbirka sljedova protutijela i njezina upotreba
SG10201606872TA (en) Anti-tie2 antibodies and uses thereof
IL226427A0 (en) Anti ccr4 antibodies and uses thereof
DK3404043T3 (da) Anti-cdh3-antistof med høj internaliseringskapacitet
EP3505536C0 (de) Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
EP2488202A4 (en) ANTIBODY THERAPY AGENTS WITH LOCAL ACTIVITY IN THE DIGESTIVE STRUCTURE
HUE041952T2 (hu) Javított anti-humán Fraktalkin ellenanyagok és alkalmazásaik
SI3173427T1 (sl) Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
EP2671078A1 (en) Anti-carbamylated protein antibodies and the risk for arthritis
IL214840A (en) Humanised antibodies with anti-tumour activity
IL199618A0 (en) Novel antibodies and their use in diagnostic methods
EP3150632A3 (en) Anti-ricin antibodies and uses thereof